Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant

Review and consensus statement

Lawrence Einhorn, Bernardo Rapoport, Jim Koeller, Steven M. Grunberg, Petra Feyer, Cynthia Rittenberg, Matti Aapro

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.

Original languageEnglish
Pages (from-to)112-116
Number of pages5
JournalSupportive Care in Cancer
Volume13
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Antiemetics
Stem Cells
Transplants
Drug Therapy
Nausea
Emetics
Serotonin 5-HT3 Receptor Antagonists
Dexamethasone
Vomiting
Therapeutics
Combination Drug Therapy
Cisplatin

Keywords

  • 5-HT3 antagonist
  • Antiemetics
  • High-dose chemotherapy
  • Multiple-day chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant : Review and consensus statement. / Einhorn, Lawrence; Rapoport, Bernardo; Koeller, Jim; Grunberg, Steven M.; Feyer, Petra; Rittenberg, Cynthia; Aapro, Matti.

In: Supportive Care in Cancer, Vol. 13, No. 2, 02.2005, p. 112-116.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Rapoport, Bernardo ; Koeller, Jim ; Grunberg, Steven M. ; Feyer, Petra ; Rittenberg, Cynthia ; Aapro, Matti. / Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant : Review and consensus statement. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 2. pp. 112-116.
@article{f3aa2aeb84204aab8c6c1867ca2067e9,
title = "Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: Review and consensus statement",
abstract = "The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.",
keywords = "5-HT3 antagonist, Antiemetics, High-dose chemotherapy, Multiple-day chemotherapy",
author = "Lawrence Einhorn and Bernardo Rapoport and Jim Koeller and Grunberg, {Steven M.} and Petra Feyer and Cynthia Rittenberg and Matti Aapro",
year = "2005",
month = "2",
doi = "10.1007/s00520-004-0704-4",
language = "English",
volume = "13",
pages = "112--116",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant

T2 - Review and consensus statement

AU - Einhorn, Lawrence

AU - Rapoport, Bernardo

AU - Koeller, Jim

AU - Grunberg, Steven M.

AU - Feyer, Petra

AU - Rittenberg, Cynthia

AU - Aapro, Matti

PY - 2005/2

Y1 - 2005/2

N2 - The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.

AB - The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.

KW - 5-HT3 antagonist

KW - Antiemetics

KW - High-dose chemotherapy

KW - Multiple-day chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=17644372750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644372750&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0704-4

DO - 10.1007/s00520-004-0704-4

M3 - Article

VL - 13

SP - 112

EP - 116

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -